Table 2 Results from meta-analyses conducted independently by Centers A and B examining measures of efficacy and safety associated with rhBMP-2
Outcome | Center | Surgical approach | No. of studies (n) | Effect size (95% CI) | Treatment advantage |
|---|---|---|---|---|---|
ODI | A | All | 12 (1368) | (0-100) -3.48 (-6.47 to -0.49) | BMP |
B | ALIF | 5 (423) | (0-50) -7.35 (-14.00 to -0.70) | BMP | |
PLF | 4 (650) | (0-50) -1.98 (-4.86 to 0.90) | Neither | ||
SF-36 PCS | A | All | 12 (1303) | (0-100) 1.93 (0.63 to 3.22) | BMP |
B | ALIF | 5 (421) | (0-100) 3.68 (0.86 to 6.49) | BMP | |
PLF | 4 (644) | (0-100) 1.10 (-0.6 to 2.86) | Neither | ||
Back pain | A | All | 12 (1326) | (0-10) -1.58 (-2.65 to -0.51) | BMP |
B | ALIF | 4 (409) | (0-20) -0.74 (1.49 to 0.00) | BMP | |
PLF | 4 (649) | (0-20) -0.31 (-0.76 to 0.15) | Neither | ||
Leg pain | A | All | 12 (1326) | (0-10) -0.59 (-1.27 to 0.09) | Neither |
B | ALIF | 4 (409) | (0-20) -0.60 (-1.28 to 0.08) | Neither | |
PLF | 4 (648) | (0-20) -0.34 (-0.82 to 0.13) | Neither | ||
Fusion | A | All | 10 (1078) | RR 1.14 (1.03 to 1.25) | BMP |
B | ALIF | 5 (416) | RR 1.05 (0.88 to 1.24) | Neither | |
PLF | 4 (637) | RR 1.16 (0.96 to 1.41) | Neither | ||
Cancer | A | All up to 48 months | 11 (1281) | RR 1.98 (0.86 to 4.54) | Neither |
B | All 24 months | 5 (1450) | RR 3.45 (1.98 to 6.00) | Control | |
All 48 months | 4 (1183) | RR 1.82 (0.84 to 3.95) | Neither |